In this episode (12.08 minutes), Medicom’s correspondent covers 6 presentations from the ASCO Gastrointestinal Cancers Symposium (ASCO-GI 2023), held in San Francisco (CA, US) from 19-21 January, 2023.
The topics discussed are:
- New standard-of-care for colorectal cancer
The phase 3 SUNLIGHT trial demonstrated that bevacizumab plus trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with trifluridine/tipiracil as a single agent in patients with refractory metastatic colorectal cancer. - Zolbetuximab plus mFOLFOX6 scores in gastric cancer
Zolbetuximab added to mFOLFOX6 improved the progression-free survival and overall survival of patients with claudin-18.2-positive HER2−negative, locally advanced, unresectable or metastatic, gastric or gastroesophageal junction adenocarcinoma, primary results of the SPOTLIGHT study revealed. - New first-line option for metastatic pancreatic duct cancer
The phase 3 NAPOLI-3 trial showed that liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) outperformed nab-paclitaxel plus gemcitabine in patients with untreated metastatic pancreatic ductal adenocarcinoma. - Radiotherapy relieves hepatic pain in HCC and liver metastasis
Single fraction radiation therapy added to best supportive care outperformed best supportive care only in reducing hepatic pain in patients with either end-stage hepatocellular carcinoma or liver metastasis. A trend was reported towards improved survival for patients receiving RT. - Novel treatment option for advanced gastric cancer
Regorafenib outperformed placebo in terms of overall survival in patients with refractory advanced gastric or oesophago-gastric junction cancer in the phase 3 INTEGRATE IIa trial, providing a new treatment option for this patient population. - Excellent outcomes of LATG/LAPG in gastric cancer
Patients with stage 1 gastric cancer displayed excellent long-term survival outcomes after laparoscopy-assisted total or proximal gastrectomy. According to the authors, the JCOG1401 study showed that laparoscopy-assisted total or proximal gastrectomy can result in comparable results as open procedures.
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Evidence-based advocacy for people affected by brain tumours Next Article
High-dose methotrexate or standard interim maintenance in young patients with ALL? »
« Evidence-based advocacy for people affected by brain tumours Next Article
High-dose methotrexate or standard interim maintenance in young patients with ALL? »
Table of Contents: ASCO GI 2023
Featured articles
Oesophageal and Gastric Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Anal and Colorectal Cancer
IMbrave 151 missed primary endpoint in advanced BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Hepatobiliary Cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Pancreatic Cancer
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Related Articles
March 12, 2021
Borderline resectable pancreatic cancer: phase 2 results
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com